WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo‐monocytic leukemia?
- 1 June 2004
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 73 (1) , 25-28
- https://doi.org/10.1111/j.1600-0609.2004.00260.x
Abstract
Abstract: The WT1 gene is considered to be highly expressed in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia and chronic myeloid leukemia and is thought to play a key role in maintaining the viability of leukemia cells. However, little is known about the WT1 gene expression levels in pediatric patients with juvenile myelo‐monocytic leukemia (JMML) and myelodysplastic syndromes (MDS). We studied WT1 expression in diagnostic bone marrow (BM) and peripheral blood (PB) samples of 90 patients with JMML, low grade MDS, advanced MDS and myelodysplasia‐related AML in BM (n = 20) and PB (n = 18) samples of normal healthy volunteer donors.Keywords
This publication has 14 references indexed in Scilit:
- Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2003
- A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseasesLeukemia, 2003
- Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometryLeukemia, 2002
- Characterization of lineage‐specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapseBritish Journal of Haematology, 2000
- Myelodysplastic Syndromes in ChildhoodOncology Research and Treatment, 2000
- The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromesLeukemia, 1999
- Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human LeukemiaBlood, 1997
- Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levelsBlood, 1996
- The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCRAnnals of Oncology, 1995